SIMPLIFLU

HELPING YOU FIGHT FLU IS WHAT WE DO — SIMPLIFY ORDERING WITH GSK FLU

2023/2024 FLU SEASON

FLUARIX QUADRIVALENT and **FLULAVAL QUADRIVALENT** are vaccines indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccines.

FLUARIX QUADRIVALENT and **FLULAVAL QUADRIVALENT** are approved for use in persons aged 6 months and older.

Fluarix Quadrivalent Influenza Vaccine

Box NDC Code: 58160-909-52

Unit NDC Code: 58160-909-41

CPT Code: 90686

ICD-10 Code: Z23

FluLaval Quadrivalent Influenza Vaccine

Box NDC Code: 19515-814-52

Unit NDC Code: 19515-814-41

CPT Code: 90686

ICD-10 Code: Z23

Presentation: Supplied in 0.5-mL, single-dose, prefilled, *Tip-Lok* syringes

Tip caps and plungers of the prefilled syringes are not made with natural rubber latex

Does not contain thimerosal

Box dimensions: 7” x 4” x 1.25” per tray of 10 syringes

2D barcodes on product and packaging

QUESTIONS?

- Call 1-855-GSK-4QIV (1-855-475-4748) or visit us at **GSKDirect.com**
- Contact your GSK Vaccines sales representative to place an order

Important Safety Information for FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT

- Do not administer FLUARIX QUADRIVALENT or FLULAVAL QUADRIVALENT to anyone with a history of severe allergic reactions (eg, anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine

Please see full Important Safety Information for FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT on reverse.

Please see accompanying full Prescribing Information for FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT.

Indication for FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT

FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT are vaccines indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccines. FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT are approved for use in persons aged 6 months and older.

Important Safety Information for FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT

- Do not administer FLUARIX QUADRIVALENT or FLULAVAL QUADRIVALENT to anyone with a history of severe allergic reactions (eg, anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine
- If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLUARIX QUADRIVALENT or FLULAVAL QUADRIVALENT should be based on careful consideration of the potential benefits and risks
- Syncope (fainting) can occur in association with administration of injectable vaccines, including FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
- If FLUARIX QUADRIVALENT or FLULAVAL QUADRIVALENT is administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the immune response may be lower than in immunocompetent persons
- In clinical trials with FLUARIX QUADRIVALENT in adults, the most common solicited local adverse reaction was pain and the most common systemic adverse reactions were muscle aches, headache, and fatigue. In children 6 through 35 months of age, the most common solicited local adverse reactions were pain and redness and the most common systemic adverse reactions were irritability, loss of appetite, and drowsiness. In children 3 through 17 years of age, the solicited local adverse reactions were pain, redness, and swelling. In children 3 through 5 years of age, the most common systemic adverse reactions were drowsiness, irritability, and loss of appetite. In children 6 through 17 years of age, the most common systemic adverse reactions were fatigue, muscle aches, headache, arthralgia, and gastrointestinal symptoms. (See Adverse Reactions section of the Prescribing Information for FLUARIX QUADRIVALENT for other potential adverse reactions and events)
- In clinical trials with FLULAVAL QUADRIVALENT in adults, the most common solicited local adverse reaction was pain and the most common solicited systemic adverse reactions were muscle aches, headache, fatigue, and arthralgia. In children 6 through 35 months of age, the most common solicited local adverse reaction was pain and the most common solicited systemic adverse reactions were irritability, drowsiness, and loss of appetite. In children 3 through 17 years of age, the most common solicited local adverse reaction was pain. In children 3 through 4 years of age, the most common solicited systemic adverse reactions were irritability, drowsiness, and loss of appetite. In children 5 through 17 years of age, the most common solicited systemic adverse reactions were muscle aches, fatigue, headache, arthralgia, and gastrointestinal symptoms. (See Adverse Reactions section of the Prescribing Information for FLULAVAL QUADRIVALENT for other potential adverse reactions and events)
- Vaccination with FLUARIX QUADRIVALENT or FLULAVAL QUADRIVALENT may not result in protection in all vaccine recipients

Please see accompanying full Prescribing Information for FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT.

Return Privileges: 15% of all seasonal GSK flu vaccine doses purchased via GSKDirect are eligible to be returned for full credit (the 15% eligibility is applied in the aggregate), unless contract or state law provides otherwise. In order to qualify for return reimbursement of eligible flu vaccine doses, customers must obtain a GSK-issued Return Goods Authorization (RGA).* The RGA can be obtained via GSKDirect or by calling the GSK Vaccine Service Center at 1-866-475-8222. Eligible flu vaccine doses returned must be received at the GSK Return Goods Vendor Inmar within the Flu Vaccine Return period. GSK will notify eligible customers of the return window begin date and end date and when the RGA will be available. Flu vaccine returns received without the RGA and/or received outside of the eligible Flu Vaccine Return period will be reimbursed Federal Excise Tax (FET) only.

*__GSK-issued RGA –__ GSK will provide customer with a document in the form of a debit memo authorizing the return of eligible flu vaccine doses. Please note: the creation of a return box label through the GSK Return Goods Vendor Inmar is not a guarantee of reimbursement and is not to be used in place of a GSK-issued RGA.

Fluarix Quadrivalent Influenza Vaccine

FluLaval Quadrivalent Influenza Vaccine

FLQLBND230006 May 2023
Produced in USA. 0002-0024-24